Sepsis is a worldwide problem that can cause devastating patient consequences and incur significant healthcare costs. But diagnosing sepsis is challenging. Delays in diagnosing sepsis and initiating treatment result in increased symptom severity and patient risk, higher rates of long-term complications and mortality, and greater costs to healthcare systems.
Early sepsis detection improves patient prognosis and reduces the cost of sepsis-related care. Beckman Coulter is currently the only company providing all IVD testing modalities for sepsis diagnosis and management.1